Oct 10, 2023 FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on October 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 92,050 shares of common stock and 46,030 restricted stock units (“RSUs”) to 12 new employees under Mirum’s 2020 Inducement…
Oct 27, 2023 FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report third quarter 2023 financial results on Thursday, November 2nd, 2023. Mirum will also host a conference call to discuss the third quarter 2023 financial results and recent corporate progress. Conference call details:Thursday, November 2nd, 20234:30 p.m. ET /…
Oct 30, 2023 – Late-breaker poster presentation accepted featuring LIVMARLI® data showing long-term maintenance of response in patients with PFIC – Four poster presentations will highlight LIVMARLI PFIC data and volixibat proof-of-concept trial data in intrahepatic cholestasis of pregnancy FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that data from its LIVMARLI and volixibat…
Jul 27, 2023 FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report second quarter 2023 financial results on Thursday, August 3, 2023. Mirum will also host a conference call to discuss the second quarter 2023 financial results and recent corporate progress. Conference call details:Thursday, August 3, 20234:30 p.m. ET…
Jul 25, 2023 FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that LIVMARLI® (maralixibat oral solution) has been authorized by Health Canada for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230725391772/en/ LIVMARLI (maralixibat oral solution) (Graphic: Business Wire) ALGS…
Jul 17, 2023 Mirum to acquire all of Travere’s rights and assets related to Cholbam® and Chenodal®Travere to receive up to $445 million with $210 million upfront and up to $235 million in potential sales-based milestonesMirum announces concurrent private placement of $210 million, funding upfront paymentExpands Mirum’s leadership in rare liver disease with two commercial…
